Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
All the vital news, analysis, and commentary curated by our industry experts.
Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli.
The Exportin 1 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Exportin 1, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for XPO1 and features dormant and discontinued projects.
Key Therapy Areas in the Exportin 1 Pipeline Drugs Market
In the XPO1 pipeline drugs market the key therapy areas are Oncology, Central Nervous System, Immunology, Genetic Disorders, Infectious Disease, and Metabolic Disorders.
Exportin 1 Pipeline Drugs Market, by Therapy Areas
For more therapy areas insights, download a free report sample
Key MoA in the Exportin 1 Pipeline Drugs Market
The key MoA in the Exportin 1 pipeline drugs market is Exportin 1 Inhibitor.
Exportin 1 Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Exportin 1 pipeline drugs market are oral, and topical.
Exportin 1 Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Exportin 1 Pipeline Drugs Market
The key molecule type in the Chromosomal Maintenance 1 pipeline drugs market is Small Molecule.
Major Companies in the Exportin 1 Pipeline Drugs Market
The major companies in the Exportin 1 pipeline drugs market are Karyopharm Therapeutics Inc, Wigen Biomedicine Technology (Shanghai) Co Ltd, Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd, and Oita University Institute of Advanced Medicine Inc.
Exportin 1 Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Exportin 1 Pipeline Drugs Market Overview
|Key Therapy Areas||Oncology, Central Nervous System, Immunology, Genetic Disorders, Infectious Disease, and Metabolic Disorders|
|Key Mechanisms of action||Exportin 1 Inhibitor|
|Key Routes of Administration||Oral, and Topical|
|Key Molecule Types||Small Molecule|
|Major Companies||Karyopharm Therapeutics Inc, Wigen Biomedicine Technology (Shanghai) Co Ltd, Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd, and Oita University Institute of Advanced Medicine Inc|
- The pipeline guide provides a snapshot of the global therapeutic landscape of Exportin 1
- The pipeline guide reviews pipeline therapeutics for Exportin 1 by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Exportin 1 therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Exportin 1 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Exportin 1
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Exportin 1
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Exportin 1 pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
CanBas Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Karyopharm Therapeutics Inc
Oita University Institute of Advanced Medicine Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
Table of Contents
Table of Contents
List of Tables
List of Figures
Global Markets Direct Report Coverage
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Overview
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Companies Involved in Therapeutics Development
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Drug Profiles
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Dormant Products
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Discontinued Products
Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) – Product Development Milestones
Featured News & Press Releases
Apr 06, 2022: Antengene’s pivotal “MARCH” study to evaluate selinexor (ATG-010) in relapsed or refractory multiple myeloma published in BMC Medicine
Mar 29, 2022: Antengene announces IND approval in China for a phase II study of Eltanexor (ATG-016) in patients with High-Risk Myelodysplastic Syndrome
Mar 16, 2022: Karyopharm announces upcoming presentations of phase 3 SIENDO study of selinexor in patients with advanced or recurrent endometrial cancer
Mar 09, 2022: Antengene announces XPOVIO approved by the TGA in Australia for the treatment of relapsed and/or refractory multiple myeloma and triple class-refractory multiple myeloma
Mar 01, 2022: Antengene announces XPOVIO regulatory approval in Singapore for the treatment of relapsed and/or refractory multiple myeloma and relapsed/refractory diffuse large B-cell lymphoma in three indications
Mar 01, 2022: Karyopharm provides U.S. regulatory update on Selinexor in advanced or recurrent Endometrial Cancer
Feb 08, 2022: Karyopharm announces Phase 3 SIENDO study meets primary endpoint with statistically significant increase in progression-free survival in patients with advanced or recurrent endometrial cancer
Jan 24, 2022: Karyopharm receives orphan drug designation from FDA for eltanexor for the treatment of myelodysplastic syndromes
Dec 29, 2021: Antengene announces first patient dosed in REACH study of ATG-016 for the treatment of advanced solid tumors
Dec 18, 2021: Antengene announces NDA approval by NMPA for XPOVIO, China’s first XPO1 inhibitor, for the treatment of adults with relapsed or refractory multiple myeloma
Dec 14, 2021: Antengene presents results of phase 1b TOUCH trial of Selinexor for the treatment of T and NK-Cell lymphoma at the 2021 American Society of Hematology (ASH) Annual Meeting
Dec 11, 2021: Karyopharm announces presentation of updated phase 2 selinexor data in patients with myelofibrosis at the American Society of Hematology 2021 Annual Meeting and Exposition
Dec 06, 2021: Karyopharm announces dosing of first patient in a new phase 2 study evaluating single-agent selinexor versus physician’s choice in previously treated myelofibrosis
Dec 02, 2021: Karyopharm completes patient recruitment in phase 3 SIENDO study of selinexor in patients with endometrial cancer
Nov 18, 2021: Antengene announces IND approval in China for a phase I/II Study of Selinexor (ATG-010) in patients with non-Hodgkin lymphoma
Expert Panel Validation
Frequently asked questions
What are the key therapy areas in the Exportin 1 pipeline drugs market?
In the Exportin 1 pipeline drugs market the key therapy areas are Oncology, Central Nervous System, Immunology, Genetic Disorders, Infectious Disease, and Metabolic Disorders.
What are the key mechanisms of action in the Exportin 1 pipeline drugs market?
In the Exportin 1 pipeline drugs market the key mechanism of action is Exportin 1 Inhibitor.
What are the key routes of administration in the Exportin 1 pipeline drugs market?
The key routes of administration in the Exportin 1 pipeline drugs market are Oral, and Topical.
What are the key molecule types in the Exportin 1 pipeline drugs market?
The key molecule type in the Exportin 1 pipeline drugs market is Small Molecule.
What are the major companies in the Exportin 1 pipeline drugs market?
In the Exportin 1 pipeline drugs market the major companies are Karyopharm Therapeutics Inc, Wigen Biomedicine Technology (Shanghai) Co Ltd, Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd, and Oita University Institute of Advanced Medicine Inc.
Undecided about purchasing this report?Enquire Before Buying
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.